

Arthrex Inc.
Ivette Galmez
Regulatory Affairs Principal Specialist
1370 Creekside Boulevard
Naples, Florida 34108-1945

Re: K233260

Trade/Device Name: Univers Revers CA Head and Adapter

Regulation Number: 21 CFR 888.3690

Regulation Name: Shoulder joint humeral (hemi-shoulder) metallic uncemented prosthesis

February 12, 2024

Regulatory Class: Class II Product Code: HSD Dated: January 10, 2024 Received: January 10, 2024

Dear Ivette Galmez:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

K233260 - Ivette Galmez Page 2

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Joseph P.

Russell -S

Digitally signed by Joseph P. Russell -S

Date: 2024.02.12 11:08:41

-05'00'

for: Farzana Sharmin, PhD

Assistant Director

DHT6A: Division of Joint Arthroplasty Devices

OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known)

K233260

Form Approved: OMB No. 0910-0120 Expiration Date: 07/31/2026

Expiration Date: 07/31/2026 See PRA Statement below.

Device Name
Univers Revers CA Head and Adapter
Indications for Use (Describe)
The Univers Revers CA humeral head and adapters are indicated for:
• salvage of a failed reverse total shoulder, with an irreparable rotator cuff tear and a well-fixed humeral stem, to an anatomic hemi-shoulder replacement; or
conversion of a primary reverse total shoulder, for the relief of pain secondary to severe rotator cuff arthropathy and an irreparable rotator cuff tear, to anatomic hemi-shoulder replacement when insufficient glenoid bone stock is encountered intraoperatively after the humeral stem has been implanted.
The patient's joint must be anatomically and structurally suited to receive the selected implant(s), and a functional deltoid muscle is necessary to use the device.
Type of Use (Select one or both, as applicable)
☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

Date Prepared	February 9, 2024
Submitter	Arthrex Inc.
	1370 Creekside Boulevard
	Naples, FL 34108-1945
Contact Person	Ivette Galmez
	Regulatory Affairs Principal Specialist
	1 (239) 643-5553 x 71263
	ivette.galmez@arthrex.com
Trade Name	Univers Revers CA Head and Adapter
Common Name	Shoulder Prosthesis
Product Code	HSD
Classification Name	21 CFR 888.3690: Shoulder joint humeral (hemi-shoulder) metallic uncemented prosthesis
Regulatory Class	
Predicate Device	K151527: Arthrex Univers Revers CA Heads and Adapters
Reference Devices	K071032: Arthrex Univers II Shoulder Prosthesis
Rejerence Devices	K221232: Univers Revers Humeral Cup Implant
	K230366: Arthrex Univers Revers Monoblock Stem Size 4/33
	K161782: Arthrex Univers Revers Shoulder Prosthesis System
	K230513: Arthrex Univers Apex OptiFit Humeral Stems
Purpose of	This 510(k) premarket notification is submitted to obtain clearance for the Univers Revers CA Head and
Submission	Adapter which is smaller than the predicate device.
Device Description	The subject device is a line extension to the Arthrex Univers Revers CA Heads and Adapters cleared in
Device Description	K151527. The subject device components are smaller and are made of the same materials (cobalt
	chromium, titanium, and UHMWPE) as the predicate. The subject devices are designed for use with the
	Arthrex implantable devices cleared in K221232, K230366, K161782, K142863 and K170414. The
	subject devices are labeled with MRI conditional claims in accordance with Arthrex labeling cleared
	under K230513.
Indications for Use	The Univers Revers CA humeral head and adapters are indicated for:
	 salvage of a failed reverse total shoulder, with an irreparable rotator cuff tear and a well-fixed
	humeral stem, to an anatomic hemi-shoulder replacement; or
	 conversion of a primary reverse total shoulder, for the relief of pain secondary to severe rotator
	cuff arthropathy and an irreparable rotator cuff tear, to anatomic hemi-shoulder replacement
	when insufficient glenoid bone stock is encountered intraoperatively after the humeral stem has
	been implanted.
	The patient's joint must be anatomically and structurally suited to receive the selected implant(s), and
	a functional deltoid muscle is necessary to use the device.
Performance Data	Dynamic fatigue testing followed by corrosion assessment per ASTM F1875, metal ion analysis, and
	disassembly testing per ASTM F1820 was performed. All samples met the acceptance criteria.
	Biocompatibility testing was conducted to demonstrate no impact to the final finished device due to
	the change of supplier. Bacterial Endotoxin per EP 2.6.14/USP <85> demonstrates that the subject
	device meets pyrogen limit specifications.
Technological	This submission expands the size range of the Univers Revers CA Heads and Adapters by introducing
Comparison	smaller size implants but with identical design features to the predicate. The subject device
•	components are made of the same materials as the predicate. The subject devices have the same
	intended use/indications, packaging, shelf life and sterilization as the predicate.
Conclusion	The subject device is substantially equivalent to the predicate in which the basic design features and
	intended use/indications are the same. The mechanical testing data demonstrates that the subject
	device performance is equivalent to the predicate device for the desired indications. Any differences
	between the subject and the predicate device are considered minor and do not raise different
	questions regarding safety or effectiveness.
	Based on the indications for use, technological characteristics, and the summary of data submitted,
	Arthrex Inc. has determined that the subject device is substantially equivalent to the currently
	marketed predicate device.